HC Wainwright Expects Reduced Earnings for Alto Neuroscience

Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) - Investment analysts at HC Wainwright reduced their Q2 2025 earnings per share (EPS) estimates for Alto Neuroscience in a note issued to investors on Tuesday, May 20th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($0.50) per share for the quarter, down from their previous forecast of ($0.48). HC Wainwright currently has a "Buy" rating and a $10.00 target price on the stock. The consensus estimate for Alto Neuroscience's current full-year earnings is ($2.54) per share. HC Wainwright also issued estimates for Alto Neuroscience's Q3 2025 earnings at ($0.71) EPS, Q4 2025 earnings at ($0.73) EPS, FY2025 earnings at ($2.48) EPS, Q1 2026 earnings at ($0.82) EPS, Q2 2026 earnings at ($0.84) EPS, Q3 2026 earnings at ($0.86) EPS, Q4 2026 earnings at ($0.67) EPS, FY2026 earnings at ($3.15) EPS, FY2027 earnings at ($3.15) EPS, FY2028 earnings at ($3.06) EPS and FY2029 earnings at ($1.72) EPS.

A number of other brokerages also recently issued reports on ANRO. William Blair reaffirmed an "outperform" rating on shares of Alto Neuroscience in a research report on Friday, March 21st. Wedbush reaffirmed a "neutral" rating and issued a $4.00 target price on shares of Alto Neuroscience in a report on Thursday, May 15th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Alto Neuroscience currently has a consensus rating of "Moderate Buy" and a consensus price target of $15.40.

Alto Neuroscience Stock Performance

Shares of ANRO stock opened at $2.87 on Thursday. The company has a debt-to-equity ratio of 0.05, a current ratio of 13.10 and a quick ratio of 13.09. The firm has a 50-day moving average of $2.34 and a 200-day moving average of $3.41. Alto Neuroscience has a one year low of $1.60 and a one year high of $17.55. The company has a market cap of $77.70 million, a P/E ratio of -1.23 and a beta of 1.87.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.06.

Institutional Trading of Alto Neuroscience

Hedge funds have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN increased its stake in shares of Alto Neuroscience by 40.0% during the 4th quarter. Wells Fargo & Company MN now owns 10,989 shares of the company's stock worth $46,000 after purchasing an additional 3,139 shares during the last quarter. Deutsche Bank AG lifted its stake in Alto Neuroscience by 31.3% in the fourth quarter. Deutsche Bank AG now owns 15,210 shares of the company's stock valued at $64,000 after purchasing an additional 3,629 shares during the last quarter. Skandinaviska Enskilda Banken AB publ bought a new position in Alto Neuroscience during the fourth quarter valued at $74,000. Jane Street Group LLC increased its position in Alto Neuroscience by 72.0% in the fourth quarter. Jane Street Group LLC now owns 18,600 shares of the company's stock worth $79,000 after buying an additional 7,783 shares during the last quarter. Finally, AQR Capital Management LLC bought a new stake in shares of Alto Neuroscience in the first quarter valued at $52,000.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.